Theravance Biopharma Inc
NASDAQ:TBPH
Theravance Biopharma Inc
NASDAQ:TBPH
Price:
9.12 USD
-0.22%
Market Closed
Updated:
Apr 28, 2024
Section:
Relative Value
The Relative Value of one
TBPH
stock under the Base Case scenario is
9.4
USD.
Compared to the current market price of 9.12 USD,
Theravance Biopharma Inc
is
Undervalued by 3%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TBPH
Relative Value
Base Case
9.4
USD
Undervaluation 3%
Valuation Multiples
Multiples Across Competitors
TBPH Competitors Multiples
Theravance Biopharma Inc Competitors
Theravance Biopharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| KY |
|
Theravance Biopharma Inc
NASDAQ:TBPH
|
438.6m USD | 7.6 | -7.9 | -5.3 | -5.1 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
696.4B USD | 20.4 | 132.9 | 60.1 | 68.9 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 17 | 47.2 | 34.6 | 37.7 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| JP |
|
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 255.8 | 9 733.7 | 1 771.8 | 4 320.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
351.8B USD | 4.3 | 8.7 | 11.6 | 15.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
332.2B USD | 5.5 | 910 | 45.2 | 88.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
185.8B GBP | 5.1 | 39 | 140.5 | 225.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.9B CHF | 4.3 | 13.5 | 9.9 | 16.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
176.2B CHF | 3 | 15.3 | 8.5 | 10 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
